S2Medical AB (publ)
STO:S2M
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.0085
0.1295
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
S2Medical AB (publ)
Cash & Cash Equivalents
S2Medical AB (publ)
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
S2Medical AB (publ)
STO:S2M
|
Cash & Cash Equivalents
kr1.4m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
|
O
|
OssDsign AB
STO:OSSD
|
Cash & Cash Equivalents
kr165.9m
|
CAGR 3-Years
50%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
|
Xvivo Perfusion AB
STO:XVIVO
|
Cash & Cash Equivalents
kr450m
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
23%
|
|
|
D
|
Doxa AB
STO:DOXA
|
Cash & Cash Equivalents
kr11.8m
|
CAGR 3-Years
121%
|
CAGR 5-Years
3%
|
CAGR 10-Years
10%
|
|
|
Bactiguard Holding AB
STO:BACTI B
|
Cash & Cash Equivalents
kr123.2m
|
CAGR 3-Years
132%
|
CAGR 5-Years
131%
|
CAGR 10-Years
N/A
|
|
|
V
|
Vimian Group AB
STO:VIMIAN
|
Cash & Cash Equivalents
€39.2m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
S2Medical AB (publ)
Glance View
S2Medical AB engages in research and development in biotechnology. The company is headquartered in Linkoping, Ostergotland. The company went IPO on 2018-11-28. The firm focuses on developing products for healing burns and chronic wounds, from debridement and granulation to reepithelialization. The firm's product portfolio includes INSTAQRETT, a sterile single-use mechanical debridement tool, the Epiprotect product line based on its collagen-mimicking Eiratex material, which includes EPIPROTECT Safestop, a blood-stilling membrane dressing, EPIPROTECT 2117, a synthetic substitute to allografts and xenografts, EPIPROTECT ULCER, dressing for treating ulcers, as well as INSTABIND bandages and Instagraft, a single-use medical device designed to treat chronic wounds with microtransplants from the patient's own skin without creating any new wounds. The firm is also the official distributor of Silverlon antimicrobial dressings for Nordic countries. In addition, it operates the S2Clinic, a wound healing center in Sweden.
See Also
What is S2Medical AB (publ)'s Cash & Cash Equivalents?
Cash & Cash Equivalents
1.4m
SEK
Based on the financial report for Jun 30, 2024, S2Medical AB (publ)'s Cash & Cash Equivalents amounts to 1.4m SEK.
What is S2Medical AB (publ)'s Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-45%
Over the last year, the Cash & Cash Equivalents growth was -17%. The average annual Cash & Cash Equivalents growth rates for S2Medical AB (publ) have been -48% over the past three years , -45% over the past five years .
You don't have any saved screeners yet
